[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-period\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-period":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,78,103,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100593071","investigation-of-the-effects-of-tele-yoga-training-in-individuals-with-lung-cancer-undergoing-lung-resection-surgery-100593071",false,"NCT07001670","Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection Surgery","The Effects of an 8-Week Tele-Yoga Program on Postoperative Recovery in Patients With Lung Cancer Undergoing Lung Resection","Inclusion Criteria:\n\n* Aged between 18 and 65 years,\n* Histologically confirmed diagnosis of Stage I-IIIA lung cancer according to the 9th edition of the AJCC Cancer Staging Manual,\n* Underwent lobectomy, pneumonectomy, segmentectomy, or wedge resection via video-assisted thoracoscopic surgery (VATS) or robot-assisted thoracoscopic surgery (RATS),\n* An estimated life expectancy of ≥6 months,\n* Karnofsky Performance Status score greater than 80% at study entry,\n* Possession of the necessary equipment and access to a stable internet connection to enable participation in online interventions.\n\nExclusion Criteria:\n\n* History of receiving radiotherapy or chemotherapy prior to surgery,\n* Presence of severe dysfunction in vital organs such as the heart, brain, kidneys, or others,\n* Having any comorbid condition that contraindicates participation in an exercise training program,\n* Presence of serious postoperative complications,\n* Cognitive impairments that hinder effective communication,\n* Current participation in a structured and regular exercise program,\n* Missing three consecutive weeks of sessions or completing less than 75% of the prescribed exercises,\n* Voluntary withdrawal from the study by the participant.","ALL","18 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled clinical trial aims to evaluate the effects of an 8-week tele-yoga intervention in individuals with lung cancer who have undergone lung resection surgery. The intervention group will receive supervised yoga sessions via online synchronous video conferencing, while the control group will continue with standard post-operative care. The primary outcome is exercise capacity (6-minute walk test), with secondary outcomes including pulmonary function, respiratory and peripheral muscle strength, physical activity level, dyspnea, fatigue, sleep quality, anxiety and depression, and quality of life. It is hypothesized that tele-yoga will improve physical and psychological recovery post-surgery and may serve as a feasible home-based pulmonary rehabilitation alternative.",[27,28],"Postoperative Period","Lung Cancer (Diagnosis)",[30,31,32,33,34,35,36,37,38,39,40],"Exercise capacity","Pulmonary function","Muscle Strength","Dyspnea","Fatigue","Anxiety","Depression","Quality of Life","Exercise Therapy","Telemedicine","Rehabilitation","RECRUITING","2026-06-06",{"date":44,"type":45},"2026-06-09","ACTUAL",{"date":47,"type":45},"2025-06-10",{"date":49,"type":21},"2026-10-10",{"name":51,"class":52},"Istanbul University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100639444","establishment-of-disease-characteristics-and-a-chinese-medicine-prognosis-risk-model-based-on-a-large-scale-database-after-coronary-revascularization-100639444","NCT07613060","Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization","Inclusion Criteria:\n\n* Diagnosis of coronary artery disease with prior coronary revascularization (PCI or CABG)\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Malignant arrhythmias, severe heart failure, myocardial disease, or structural heart disease\n* Severe pulmonary insufficiency, severe liver or kidney dysfunction, severe electrolyte disturbances\n* Pregnancy or breastfeeding\n* Severe psychiatric disorders, malignant tumors, hematologic diseases, rheumatic immune diseases, or severe infection\n* Poor compliance or any other reason making the participant unsuitable for the study",{"count":61,"type":21},600,"12 Months","OBSERVATIONAL","This study aims to develop a risk prediction model for patients who have undergone coronary revascularization (such as stent placement or bypass surgery). After these procedures, some patients still experience heart-related problems like chest pain, heart attack, or rehospitalization. This study will enroll 600 patients from multiple hospitals in China and follow them for 12 months. At enrollment and at 12, 24, 36, and 48 weeks after surgery, researchers will collect clinical information (including traditional Chinese medicine symptoms, blood tests, heart imaging) and biological samples (blood and tongue coating). Using artificial intelligence, the study will build a predictive model that combines Western medical data with traditional Chinese medicine characteristics. The goal is to better identify patients at higher risk of future heart events, so that personalized prevention and management can be provided. The study does not involve any experimental treatment or intervention - it is purely observational.",[66,27,67],"Coronary Artery Disease","Myocardial Revascularization","NOT_YET_RECRUITING","2026-05-21",{"date":71,"type":45},"2026-05-29",{"date":73,"type":21},"2026-07-01",{"date":75,"type":21},"2028-12-31",{"name":77,"class":52},"Liu Qiang",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":53},"100610751","home-monitoring-study-for-surgical-patients-100610751","NCT07231653","Home Monitoring Study for Surgical Patients","Inclusion Criteria:\n\n* Clinically stable patients requiring routine postoperative monitoring in the absence of any acute illness following surgery.\n* Able to use a smartphone or tablet for the monitoring system.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or conditions that may interfere with the use of home monitoring devices.\n* Currently participation in other clinical trials involving vital sign monitoring.\n* Unable to provide informed consent.","80 Years",{"count":86,"type":21},69,"This clinical trial is designed to evaluate the accuracy, usability, and patient compliance of the Wellvii VitalDetect, an FDA-cleared (510(k) K231625), Class II medical device intended for non-invasive monitoring of vital signs including blood pressure, pulse rate, and temperature. The study will focus on comparing measurements obtained in a home environment using the device to those collected in a clinical setting, with the goal of validating the device's performance for real-world, at-home use.\n\nThe Wellvii VitalDetect is a portable, battery-operated, spot-check monitor that uses finger-based technology for most parameters and an infrared sensor for forehead-based, non-contact temperature readings. It is designed for use by adults (18 years or older) in a home environment and is not intended for continuous monitoring. In addition to the cleared vital signs, the device displays other wellness parameter for general health tracking. A smartphone application supports the user experience by delivering usage instructions and data display.\n\nThe study will assess:\n\n* Measurement accuracy compared to standard clinical instruments\n* Patient ease-of-use and engagement with the device\n* Adherence to regular self-monitoring schedules\n* Overall user satisfaction and confidence I home-based monitoring\n\nThis research will contribute to the growing body of evidence supporting remote patient monitoring solutions and aims to advance the adoption of decentralized technology-enabled healthcare delivery.\n\nThe study aligns with Wellvii Inc.'s mission to transform healthcare delivery by enabling continuous, connected health monitoring from the home. The ultimate goal is to empower patients and healthcare providers with real-time, clinically actionable health at a that can lead to earlier intervention, improved outcomes, and reduced system burden.",[89,27],"Patient Monitoring",[91,92,93],"Wellvii VitalDetect","Remote patient monitoring","Postoperative monitoring","2026-05-04",{"date":96,"type":45},"2026-05-06",{"date":98,"type":21},"2026-06-01",{"date":100,"type":21},"2027-12-31",{"name":102,"class":52},"University of Alberta",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":113,"studyType":63,"phases":4,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":53},"100612796","romanian-validation-and-cross-cultural-adaptation-of-the-qor-15ro-100612796","NCT07258238","Romanian Validation and Cross-cultural Adaptation of the QoR-15Ro","Romanian Validation and Cross-cultural Adaptation of the QoR-15 Post-anesthetic Recovery Quality Questionnaire: The QoR-15Ro","QoR-15Ro","Inclusion Criteria:\n\n* Patients over 18 years old.\n* Comprehensive and sign informed consent.\n* Knows and understands the Romanian language.\n* Undergo a scheduled surgical intervention under any type of anesthetic procedure from the specialties of general surgery, urology, neurosurgery, plastic and reconstructive surgery.\n* Score \\> 26 points in the Mini Mental State Examination (MMSE) test.\n\nExclusion Criteria:\n\n* Patients under 18 years old.\n* Not having signed the informed consent.\n* Not knowing or understanding the Romanian language.\n* Surgical intervention from other specialties than general surgery, urology, neurosurgery, plastic and reconstructive surgery.\n* Score \\\u003C 27 points in the Mini Mental State Examination (MMSE) test.",{"count":112,"type":21},250,"15 Days","Optimal postoperative recovery after any surgical procedure requiring anesthesia is essential to achieving high-quality care. The Quality of Recovery questionnaire (QoR-15) was validated by its authors in 2013 in the study \"Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15.\" This instrument enables a comprehensive evaluation by integrating traditional physiological measures with the patient's subjective perception of their health status. With the consent of the original author, the present study aims to validate the Romanian version of the questionnaire and adapt it to our clinical environment.",[116,117,118,119,27],"Humans","Anesthesia","Recovery","Postoperative Care",[121,122,123],"Quality of Recovery","Postoperative Recovery","QoR-15","2025-12-01",{"date":126,"type":45},"2025-12-08",{"date":128,"type":21},"2026-01-01",{"date":130,"type":21},"2026-06-30",{"name":132,"class":52},"SUUMC Central Military Hospital Dr Carol Davila",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":53},"100563081","positive-pressure-therapy-to-optimize-lung-function-after-heart-surgery-100563081","NCT06611527","Positive Pressure Therapy to Optimize LUNG Function After Heart Surgery","Comparison Between Two Methods of Positive Pressure Therapy in the Prevention of Pulmonary Complications in the Immediate Postoperative Period of Cardiac Surgery: a Prospective, Randomized Clinical Trial","PRO-LUNGHS","Inclusion Criteria:\n\n* Immediate postoperative period of myocardial revascularization and\u002For valve replacement or plastic surgery;\n* Patients in the preoperative period at risk of developing pulmonary complications, characterized by the presence of at least 2 of the following risk factors: age ≥ 70 years, productive cough, diabetes, history of smoking, chronic obstructive pulmonary disease (COPD) defined by forced expiratory volume in 1 second (FEV1) lower than 75% of predicted, body mass index (BMI) ≥ 27 kg\u002Fm2, or only FEV1 lower than 80% and FEV1\u002Fforced vital capacity (FVC) ratio lower than 70% of predicted; OR patients in the postoperative period (up to 12 hours after extubation) with mild to moderate complications characterized by a pulmonary complication score lower than 3.\n\nExclusion Criteria:\n\n* Hemodynamic instability characterized by mean arterial pressure (MAP) lower than 60mmHg and\u002For acute arrhythmia of any etiology;\n* Need for intra-aortic balloon;\n* Duration of invasive mechanical ventilation exceeding 24 hours after surgery;\n* Pulmonary complication score ≥ grade 3;\n* Presence of signs of acute respiratory failure, such as respiratory rate (f) ≥ 25 breaths\u002Fmin and use of accessory muscles;\n* Chest tube with air leak;\n* Use of a pacemaker or implantable or external cardioverter-defibrillator.",{"count":142,"type":21},156,[24],"The most common cardiac surgeries are myocardial revascularization and valve replacement or plastic surgery. In the postoperative period of cardiac surgeries, the incidence of pulmonary complications ranges from 30% to 50% and is associated with increased length of hospital stay and morbidity and mortality. To reduce or minimize the occurrence of these complications, respiratory physiotherapy employs positive pressure reexpansion therapies, such as continuous positive airway pressure (CPAP) and positive pressure support with positive end-expiratory pressure (PS+PEEP).\n\nThe goal of this clinical trial is to compare the effects of two positive pressure therapies, CPAP versus PS+PEEP, on the incidence of pulmonary complications in patients in the postoperative period of myocardial revascularization and valve replacement or plastic surgery, with mild to moderate pulmonary dysfunction.\n\nThe main question it aims to answer is: Do patients in the immediate postoperative period of myocardial revascularization or valve replacement\u002Fplastic surgery, exhibiting mild to moderate pulmonary dysfunction, experience a comparable reversal of pulmonary conditions when treated with PS+PEEP versus CPAP?\n\nParticipants will undergo the following assessments: spirometry, respiratory muscle strength testing, handgrip strength testing, and electrical impedance tomography.\n\nIn the immediate postoperative period, participants will be randomized into two treatment groups: • Control Group PS+PEEP - application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml\u002Fkg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%; • Experimental Group CPAP - application of CPAP at 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.",[27,146,147,148,149,150],"Physical Therapy Modalities","Continuous Positive Airway Pressure","Respiratory Function Tests","Pulmonary Atelectasis","Heart Surgery","2025-04-08",{"date":153,"type":45},"2025-04-10",{"date":155,"type":45},"2025-01-08",{"date":157,"type":21},"2027-12",{"name":159,"class":52},"Federal University of São Paulo"]